Anti-Infectious Agents against MRSA

被引：48

作者：

Koyama, Nobuhiro ^{[1
]}

Inokoshi, Junji ^{[1
]}

Tomoda, Hiroshi ^{[1
]}

机构：

[1] Kitasato Univ, Grad Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan

来源：

MOLECULES | 2013年 / 18卷 / 01期

关键词：

MRSA; anti-infectious agents; peptidoglycan; teichoic acid; virulence factors; RESISTANT STAPHYLOCOCCUS-AUREUS; STREPTOMYCES SP K04-0144; CELL-WALL BIOSYNTHESIS; METHICILLIN-RESISTANT; IMIPENEM ACTIVITY; BETA-LACTAMS; UNDECAPRENYL PYROPHOSPHATE; PEPTIDOGLYCAN SYNTHESIS; STRUCTURE ELUCIDATION; BIOLOGICAL-ACTIVITIES;

D O I：

10.3390/molecules18010204

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Clinically useful antibiotics, beta-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described.

引用

页码：204 / 224

页数：21

共 51 条

[1] β-Lactam synthetase:: A new biosynthetic enzyme [J].

Bachmann, BO ;

Li, RF ;

Townsend, CA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9082-9086

[2]

BERGERBACHI B, 1989, MOL GEN GENET, V219, P263

[3] Staphylococcus aureus and Bacillus subtilis W23 Make Polyribitol Wall Teichoic Acids Using Different Enzymatic Pathways [J].

Brown, Stephanie ;

Meredith, Timothy ;

Swoboda, Jonathan ;

Walker, Suzanne .

CHEMISTRY & BIOLOGY, 2010, 17 (10) :1101-1110

[4] Bacterial cell wall assembly: still an attractive antibacterial target [J].

Bugg, Timothy D. H. ;

Braddick, Darren ;

Dowson, Christopher G. ;

Roper, David I. .

TRENDS IN BIOTECHNOLOGY, 2011, 29 (04) :167-173

[5]

Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P765

[6]

CHAMBERLAND S, 1995, 35 INT C ANT AG CHEM, pF138

[7] Non-Bisphosphonate Inhibitors of Isoprenoid Biosynthesis Identified via Computer-Aided Drug Design [J].

Durrant, Jacob D. ;

Cao, Rong ;

Gorfe, Alemayehu A. ;

Zhu, Wei ;

Li, Jikun ;

Sankovsky, Anna ;

Oldfield, Eric ;

McCammon, J. Andrew .

CHEMICAL BIOLOGY & DRUG DESIGN, 2011, 78 (03) :323-332

[8] Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp K04-0144 -: II.: Biological activities [J].

Fukumoto, Atsushi ;

Kim, Yong-Pil ;

Hanaki, Hideaki ;

Shiomi, Kazuro ;

Tomoda, Hiroshi ;

Omura, Satoshi .

JOURNAL OF ANTIBIOTICS, 2008, 61 (01) :7-10

[9] Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp K04-0144 -: I.: Taxonomy, fermentation, isolation and structural elucidation [J].

Fukumoto, Atsushi ;

Kim, Yong-Pil ;

Matsumoto, Atsuko ;

Takahashi, Yoko ;

Shiomi, Kazuro ;

Tomoda, Hiroshi ;

Omura, Satoshi .

JOURNAL OF ANTIBIOTICS, 2008, 61 (01) :1-6

[10]

Fulco Patricia, 2006, Expert Rev Anti Infect Ther, V4, P939, DOI 10.1586/14787210.4.6.939

← 1 2 3 4 5 6 →